Cannabis and Ankylosing Spondylitis

Plain-language summary

Ankylosing spondylitis is an autoimmune disease that causes inflammation of the spine and sacroiliac joints. Over years, it can lead to fused vertebrae, chronic back pain, morning stiffness, fatigue, and disrupted sleep. Standard treatment starts with NSAIDs and exercise, and escalates to biologics (TNF or IL-17 inhibitors) that actually slow the disease ^[1][2].

Cannabis enters this picture as a symptom tool. Surveys of people with rheumatic diseases — including AS — find that a meaningful minority use cannabis, mostly for pain and sleep, and most report subjective benefit ^[3][4]. That is not the same as saying it works in a controlled trial. No randomized trial has tested cannabis, THC, or CBD specifically in AS patients. Everything below is either extrapolated from other chronic pain conditions or is patient-reported.

This article is not medical advice. AS is a progressive disease. Decisions about treatment — including whether to add or substitute cannabis — should be made with a rheumatologist.

What probably works (relatively speaking)

Nothing in AS specifically meets a "probably works" bar. The closest we can get is indirect evidence from adjacent conditions.

• Chronic non-cancer pain, generally. Systematic reviews find modest but real reductions in chronic pain from cannabinoids, with an NNT roughly in the 10–24 range depending on the review Strong evidence ^[5][6]. AS pain is chronic, inflammatory, and often neuropathic-flavored around entheses, so some of this likely generalizes — but "likely" is doing work here.
• Sleep in chronic pain populations. Cannabinoids improve self-reported sleep in people with chronic pain conditions Weak / limited ^[5][7]. Since poor sleep is a major AS complaint and worsens next-day pain, this is arguably the most defensible use case.

Even here, "probably works" means "probably helps symptoms in a fraction of users," not "probably helps AS."

What might work

• Morning stiffness. Patients frequently report that an evening dose reduces morning stiffness Anecdote. Plausible via improved sleep and pain modulation, but untested in AS.
• Opioid reduction. Observational data in chronic pain populations suggest some patients reduce opioid use when adding cannabis Weak / limited ^[8]. Relevant because a subset of AS patients end up on opioids when NSAIDs are contraindicated.
• CBD for inflammation. CBD has anti-inflammatory effects in preclinical models, including in cell and animal models relevant to arthritis Weak / limited ^[9]. Human trials in inflammatory arthritis are absent or negative. One small RCT of a synthetic cannabinoid in rheumatoid arthritis (Sativex, nabiximols) showed modest pain and sleep benefit but no measurable change in inflammatory markers ^[10]. AS is not RA, but this is the closest analog we have.
• Fatigue and mood. Common in AS, sometimes helped subjectively by cannabis Anecdote. Also commonly worsened by daily heavy use — this cuts both ways.

What doesn't work or has weak evidence

• Slowing disease progression / preventing spinal fusion. No evidence. Do not expect cannabis to replace a TNF or IL-17 inhibitor No data.
• Reducing objective inflammation (CRP, ESR, MRI activity). No human evidence in AS. Preclinical anti-inflammatory findings have not translated into measurable disease-activity reduction in inflammatory arthritis trials to date No data.
• "Indica for pain, sativa for day." The indica/sativa dichotomy does not reliably predict effects; chemovar (cannabinoid + terpene profile) matters more, and even that is only loosely predictive Disputed ^[11]. Choose products by their lab-tested cannabinoid content, not by the label on the jar.
• CBD-only products for significant AS pain. Isolated CBD at commercially typical doses (10–50 mg) has not shown meaningful pain relief in well-controlled chronic pain trials Weak / limited ^[12]. Higher doses (hundreds of mg) have some signal but also cost, drug interactions, and liver enzyme concerns.

What we don't know

• Whether cannabis affects long-term radiographic progression of AS. Nobody has looked.
• Whether cannabis interacts meaningfully with biologics (TNF inhibitors, IL-17 inhibitors, JAK inhibitors). No specific studies; theoretical interactions via CYP450 exist particularly for CBD and JAK inhibitors Weak / limited.
• Optimal THC:CBD ratio, dose, or route for AS symptoms.
• Whether cannabis reduces or increases the risk of AS-associated conditions like uveitis, IBD, or cardiovascular disease.
• Whether chronic use affects fatigue, which is one of the most disabling features of AS.

Comparison with standard treatments

| Treatment | Reduces pain | Reduces stiffness | Slows disease | Evidence | |---|---|---|---|---| | NSAIDs (first line) | Yes | Yes | Possibly slows radiographic progression | Strong ^[1] | | TNF inhibitors (e.g., adalimumab) | Yes | Yes | Yes | Strong ^[2] | | IL-17 inhibitors (e.g., secukinumab) | Yes | Yes | Yes | Strong ^[2] | | Exercise / physical therapy | Yes | Yes | Improves function | Strong ^[1] | | Cannabis (THC-dominant) | Modest, extrapolated | Anecdotal | No | Weak / none in AS | | CBD (isolated) | Minimal at typical doses | No data | No | Weak |

The honest framing: cannabis competes with acetaminophen and sleep aids in the AS toolkit, not with biologics or NSAIDs. It is adjunctive.

Risks and interactions

• Cardiovascular. AS itself raises cardiovascular risk. Smoked cannabis and high-dose THC can raise heart rate and blood pressure acutely and are associated with elevated cardiovascular event risk in observational data Weak / limited ^[13]. If you use cannabis, non-combusted routes (vaporizer, edibles, tinctures) are more defensible.
• Drug interactions. CBD inhibits CYP3A4 and CYP2C9, which can raise levels of some medications. Clinically relevant interactions are documented with warfarin and some anticonvulsants; interactions with biologics are not well characterized but JAK inhibitors are metabolized by CYP3A4 Weak / limited ^[14].
• NSAID interactions. No direct pharmacologic interaction, but relying on cannabis to "replace" NSAIDs may reduce the disease-modifying benefit NSAIDs appear to provide in AS.
• Cannabis use disorder. Roughly 1 in 10 adult users develop a use disorder; higher with daily use and high-THC products Strong evidence ^[15].
• Mental health. THC can worsen anxiety and, at high doses or in vulnerable individuals, trigger psychotic symptoms Strong evidence ^[15].
• Cannabinoid hyperemesis syndrome with chronic heavy use — sometimes misdiagnosed as an AS-associated GI issue.

Bottom line: If cannabis helps you sleep and take the edge off pain, that is a legitimate use. Keep taking your prescribed AS treatment. Tell your rheumatologist. Prefer non-smoked routes. Start low, go slow, and reassess whether it is actually helping after a few weeks — subjective benefit fades and tolerance builds.

This article is educational and is not medical advice. Talk to a rheumatologist before changing your treatment.

Sources

How this page was made

Related

• Cannabis and Chronic Pain — What the evidence actually says about cannabis for long-term pain, separated from the mark...
• Cannabis and Rheumatoid Arthritis — What the evidence actually says about using cannabis, THC, and CBD for rheumatoid arthriti...